Evidence map›Paper›PMID 41767212›Full record

ArticleGynecologic oncology reports2026

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials.

Alex A Francoeur, Su-Ying Liang, Brittany File, Eunji Choi, Max Brameld, Michael T Richardson, Caitlin R Johnson, Daniel S Kapp, Krishnansu S Tewari, John K Chan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alex A FrancoeurDepartment of Obstetrics and Gynecology, University of California, Irvine, Orange, CA, USA.
Su-Ying LiangPalo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, CA, USA.
Brittany FileDepartment of Obstetrics and Gynecology, University of California, Irvine, Orange, CA, USA.
Eunji ChoiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Max BrameldPalo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, CA, USA.
Michael T RichardsonDepartment of Obstetrics and Gynecology, University of California Los Angeles, Los Angeles, CA, USA.
Caitlin R JohnsonPalo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, CA, USA.
Daniel S KappDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Krishnansu S TewariDepartment of Obstetrics and Gynecology, University of California, Irvine, Orange, CA, USA.
John K ChanDivision of Gynecologic Oncology, California Pacific / Palo Alto / Sutter Health Research Institute, San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The purpose of this project was to evaluate the cost-effectiveness of novel FDA approved regimens incorporating immunotherapy into upfront treatment with chemotherapy in advanced or recurrent endometrial cancer in the mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) cohorts. Methods: Partitioned survival models were established based on the RUBY, NRG-GY 018, and DUO-E trials, as well as available FDA data. Incremental cost-effectiveness ratios (ICERs) were estimated based on quality adjusted progression free life years saved (QA-PFLYS). Tree Age software was used to perform partitioned survival modeling. Outcomes for dMMR and pMMR groups were compared based on the current FDA approvals. Costs were obtained from Redbook Micromedex pricing and adjusted for inflation from study activation to public dissemination of trial results. Results: The addition of pembrolizumab, dostarlimab, or durvalumab to chemotherapy in patients with dMMR tumors resulted in improvements in progression free life years saved. Based on QA-PFLYS, the ICER for pembrolizumab was $217,713, followed by $351,280 for durvalumab, and $451,750 for dostarlimab. When continuing durvalumab for 2 years, the ICER was $262,087. When looking at patients with pMMR tumors, the ICER for pembrolizumab was $250,535 while the ICER for dostarlimab was $1,349,776. Conclusions: Recognizing existing differences in study design, both pembrolizumab and durvalumab may be more cost effective than dostarlimab in our model. This appears to largely be driven by differences in duration of maintenance therapy rather than differences in effectiveness or individual drug cost. Immunotherapy does not appear to be as cost effective in the pMMR population.

Indexed as

Advanced endometrial cancerCost effectivenessDostarlimabDurvalumabImmunotherapyPembrolizumabRecurrent endometrial cancer

Identifiers

PMID41767212
PMCPMC12938156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.